CHMP nod for denecimig is a minor positive but does not shift Novo's obesity-driven thesis

What happened

Novo Nordisk's denecimig received a positive CHMP opinion for hemophilia A in the EU, adding another rare disease asset with potential 2026 launch. This regulatory step is a modest positive but does not address the core challenges in the obesity franchise, where pricing pressure and Lilly's competition remain the dominant drivers. The company's investment case remains heavily tied to semaglutide economics, particularly oral Wegovy share and net pricing, as outlined in the latest deep-value report. Denecimig's EU opportunity is likely small relative to the diabetes and obesity segments, which generated over 90% of 2025 sales. Investors should treat this news as a peripheral positive and maintain focus on the upcoming Capital Markets Day and CagriSema FDA decision for any thesis-relevant shifts.

Implication

Denecimig approval adds a small diversification benefit but does not resolve the uncertainties around oral Wegovy pricing, Lilly competition, and pipeline durability. The stock remains in a range where entry near $39 is attractive and trimming above $52 is prudent. Focus remains on evidence that oral share, dose mix, and realized pricing improve together over the next two quarters.

Thesis delta

No material change to thesis. Denecimig contributes a minor rare disease revenue stream but does not alter the core obesity competitive dynamics or the WAIT rating. The thesis remains that Novo needs to demonstrate stable net revenue per patient in oral GLP-1 before a re-rating.